This conference poster presents the development of iPSC-derived ventricular cardiomyocytes (YBLiCardio) from an in-house human iPSC line to support translational cardiac research. The cells demonstrated high viability, strong plating efficiency, and expression of key cardiac markers, indicating successful differentiation and maturation.

Comprehensive characterization using flow cytometry, RNA sequencing, immunofluorescence, and electrophysiological analysis confirmed their functional similarity to primary cardiac cells. These findings highlight the potential of YBLiCardio cardiomyocytes as a reliable platform for drug discovery, toxicity testing, and cardiac safety studies.